BrainStorm chooses Worldwide as CRO for Phase III ALS trial

US-based biotechnology company BrainStorm Cell Therapeutics has chosen Worldwide Clinical Trials as the clinical research organisation (CRO) for its upcoming Phase III clinical trial of NurOwn for treatment of patients with amyotrophic lateral sclero …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news